AVXL (Anavex Life Sciences) EBIT: $-39.99 Mil (TTM As of Dec. 2025)

What is Anavex Life Sciences EBIT?

Anavex Life Sciences AVXL -0.97% 30 EBIT is $-39.99 Mil as of Dec. 2025. GuruFocus rates AVXL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Anavex Life Sciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was $-6.78 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-39.99 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Anavex Life Sciences's annualized ROC % for the quarter that ended in Dec. 2025 was -1,233.09%. Anavex Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Anavex Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -37.91%.

Anavex Life Sciences (NAS:AVXL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Anavex Life Sciences's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

	ROC % (Q: Dec. 2025 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2025 )	+	Invested Capital (Q: Dec. 2025 ))	/ count )
=	-27.128 * ( 1 - 0% )	/	( (2.367	+	2.033)	/ 2 )
=	-27.128	/	2.2
=	-1,233.09 %

where

	Invested Capital		(Q: Sep. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	103.815	-	6.579	-	( 102.577	-	max(0, 8.946	-	103.815	+	102.577	))
=	2.367

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	132.989	-	4.338	-	( 131.749	-	max(0, 6.371	-	132.989	+	131.749	))
=	2.033

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Anavex Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2025 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2025		Q: Dec. 2025
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-27.128	/	( ( (0 + max(-8.517, 0))	+	(0 + max(-5.975, 0)) )	/	2 )
=	-27.128	/	( ( 0	+	0 )	/	2 )
=	-27.128	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Sep. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.429)	-	(6.579	+	0.805	+	1.562)
=	-8.517

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.39600000000002)	-	(4.338	+	0.805	+	1.228)
=	-5.975

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Anavex Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2025 )
	=	-39.991	/	105.481
	=	-37.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences EBIT Related Terms

Anavex Life Sciences EBIT Historical Data

* Premium members only.

The historical data trend for Anavex Life Sciences's EBIT can be seen below:

Anavex Life Sciences EBIT Chart

Anavex Life Sciences Annual Data

Trend

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

Sep25

EBIT

Get a 7-Day Free Trial

-37.64

-47.62

-46.54

-43.00

-46.38

Anavex Life Sciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
EBIT	Get a 7-Day Free Trial															-13.58	-12.42	-14.31	-6.49	-6.78

AVXL vs ZNTL, HUMA, SABS: EBIT Comparison

For the Biotechnology subindustry, Anavex Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anavex Life Sciences EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's EV-to-EBIT falls into.

Save Embed

30GF Score

Anavex Life Sciences Corp AVXL

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Anavex Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.99 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of $-39.99 Mil mean?

Anavex Life Sciences (AVXL) has a EBIT of $-39.99 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anavex Life Sciences.

Is Anavex Life Sciences' EBIT too high?

Anavex Life Sciences' current EBIT is $-39.99 Mil. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.

How does Anavex Life Sciences' EBIT compare to ZNTL and HUMA?

Anavex Life Sciences' EBIT of $-39.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anavex Life Sciences. Anavex Life Sciences's current EBIT is $-39.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Anavex Life Sciences stock overvalued right now?

Anavex Life Sciences (AVXL) has a current EBIT of $-39.99 Mil. The current EBIT is $-39.99 Mil. Anavex Life Sciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current EBIT is $-39.99 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anavex Life Sciences Business Description

Industry Healthcare Biotechnology

Comparable Companies ZNTL HUMA SABS TRDA ACIU ELDN MGNX ARMP CNTX TARA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges 0HFR:UK 12X1:Germany

Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website https://www.anavex.com

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

30GF Score

Get the complete analysis for AVXL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.56

Price

View AVXL Analysis

See EBIT data for all stocks →